apixaban
bms,pfizer
['apollo', 'apixaban']
apollo trial: in clinically stable covid-19 patients w/ additional risk factors for thrombotic complications, treatment w/ apixaban 2.5 mg twice daily did not improve number of days alive and out of hospital. no major bleeding observed. #esccongress #esc2022 
Non-Profit Founder/Leader | ?? Doc | Artist | Scientist | Educator | News Anchor https://t.co/usmuA3tKft | RT ? endorse | Disclaimer: https://t.co/bwmE2O3U5W